

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Bortezomib for induction therapy prior to high dose chemotherapy and autologous stem cell transplantation for the treatment of multiple myeloma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Myeloma mostly affects the elderly population, who often have other concomitant conditions and so there may be an impact on the equality of access for these patients.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

Treatment of myeloma is related to possible co-morbidities and not age. Attendees at the scoping workshop did not consider this to be an issue of the equality legislation.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No change to the draft scope was required.
--

- | |
|--|
| 4. Have any stakeholders identified additional issues during the scoping |
|--|

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of bortezomib for induction therapy prior to high dose chemotherapy and autologous stem cell transplantation for the treatment of multiple myeloma

Issue date: November 2012

process, and, if so, have changes to the matrix been made?

No additional issues related to potential equality issues have been identified during the scoping process.

Approved by Associate Director: Frances Sutcliffe

Date: 12 November 2012